1 of 3
FEATURED COMPANIES
- Astellas Pharma
- Celgene
- Galera Therapeutics
- Izun Pharma Ltd
- Otsuka Pharmaceuticals
- Soligenix
- MORE
This “Stomatitis - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Stomatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Stomatitis: Overview
Stomatitis is a sore or inflammation inside of the mouth. The sore can be in the cheeks, gums, inside of the lips, or on the tongue. The two main forms of stomatitis are herpes stomatitis, also known as a cold sore, and aphthous stomatitis, also known as a canker sore. An infection of the herpes simplex 1 (HSV-1) virus causes herpes stomatitis. It is more common in young children between the ages of 6 months and 5 years. Stomatitis is usually indicated by multiple blisters that occur in the: gums, palate, cheeks, tongue and lip border. Treatment will depend on the type of stomatitis. The antiviral drug acyclovir (Zovirax) can treat herpes stomatitis. Aphthous stomatitis is usually not severe and does not need treatment. If pain is significant or sores are larger, topical creams with benzocaine can be applied.
"Stomatitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Stomatitis pipeline landscape is provided which includes the disease overview and Stomatitis treatment guidelines. The assessment part of the report embraces, in depth Stomatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stomatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Stomatitis R&D. The therapies under development are focused on novel approaches to treat/improve Stomatitis.
Stomatitis Emerging Drugs Chapters
This segment of the Stomatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Stomatitis Emerging Drugs
GC4419: Galera Therapeutics
GC4419, also known as avasopasem manganese is a Superoxide dismutase modulators being investigated in phase III clinical trials for stomatitis.
IZN-6N4: Izun Pharmaceuticals
IZN-6N4 is designed to prevent and treat severe oral mucositis (SOM) in head and neck cancer patients. SOM, which occurs in about 70% of these patients, comprises the painful and debilitating ulcerated sores that develop in the mouth and throat of radiation therapy patients. The drug is in phase II stage of development.
EC-18: Enzychem Lifesciences Corporation
EC-18 is an immune modulator, which has an unique mechanism of action called PETA (Pattern Recognition Receptor Endocytic Trafficking Accelerator) which accelerates the PRR-mediated endocytosis, endosome formation, ROS generation and recycle of PRRs such as TLR3, 4 and 7 etc. so that EC-18 shortens the duration of inflammatory immune response by quickly removing the PAMP/DAMP associated danger signals. As a result of the early termination of immune response, EC-18 contributes the rapid resolution of inflammation and early return to homeostasis. The clinical trials for EC-18 are in phase II stage for the treatment of patients with chemo radiation induced oral mucositis
Stomatitis: Therapeutic Assessment
This segment of the report provides insights about the different Stomatitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Stomatitis
There are approx. 20+ key companies which are developing the therapies for Stomatitis. The companies which have their Stomatitis drug candidates in the most advanced stage, i.e. phase III includes Galera Therapeutics.
Phases
This report covers around 20+ products under different phases of clinical development like
Stomatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Stomatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stomatitis drugs.
Stomatitis Report Insights
Current Treatment Scenario and Emerging Therapies:
This report will be delivered within 2 business days.
Geography Covered
- Global coverage
Stomatitis: Overview
Stomatitis is a sore or inflammation inside of the mouth. The sore can be in the cheeks, gums, inside of the lips, or on the tongue. The two main forms of stomatitis are herpes stomatitis, also known as a cold sore, and aphthous stomatitis, also known as a canker sore. An infection of the herpes simplex 1 (HSV-1) virus causes herpes stomatitis. It is more common in young children between the ages of 6 months and 5 years. Stomatitis is usually indicated by multiple blisters that occur in the: gums, palate, cheeks, tongue and lip border. Treatment will depend on the type of stomatitis. The antiviral drug acyclovir (Zovirax) can treat herpes stomatitis. Aphthous stomatitis is usually not severe and does not need treatment. If pain is significant or sores are larger, topical creams with benzocaine can be applied.
"Stomatitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Stomatitis pipeline landscape is provided which includes the disease overview and Stomatitis treatment guidelines. The assessment part of the report embraces, in depth Stomatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stomatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Stomatitis R&D. The therapies under development are focused on novel approaches to treat/improve Stomatitis.
Stomatitis Emerging Drugs Chapters
This segment of the Stomatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Stomatitis Emerging Drugs
GC4419: Galera Therapeutics
GC4419, also known as avasopasem manganese is a Superoxide dismutase modulators being investigated in phase III clinical trials for stomatitis.
IZN-6N4: Izun Pharmaceuticals
IZN-6N4 is designed to prevent and treat severe oral mucositis (SOM) in head and neck cancer patients. SOM, which occurs in about 70% of these patients, comprises the painful and debilitating ulcerated sores that develop in the mouth and throat of radiation therapy patients. The drug is in phase II stage of development.
EC-18: Enzychem Lifesciences Corporation
EC-18 is an immune modulator, which has an unique mechanism of action called PETA (Pattern Recognition Receptor Endocytic Trafficking Accelerator) which accelerates the PRR-mediated endocytosis, endosome formation, ROS generation and recycle of PRRs such as TLR3, 4 and 7 etc. so that EC-18 shortens the duration of inflammatory immune response by quickly removing the PAMP/DAMP associated danger signals. As a result of the early termination of immune response, EC-18 contributes the rapid resolution of inflammation and early return to homeostasis. The clinical trials for EC-18 are in phase II stage for the treatment of patients with chemo radiation induced oral mucositis
Stomatitis: Therapeutic Assessment
This segment of the report provides insights about the different Stomatitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Stomatitis
There are approx. 20+ key companies which are developing the therapies for Stomatitis. The companies which have their Stomatitis drug candidates in the most advanced stage, i.e. phase III includes Galera Therapeutics.
Phases
This report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
Stomatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Stomatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stomatitis drugs.
Stomatitis Report Insights
- Stomatitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Stomatitis drugs?
- How many Stomatitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Stomatitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Stomatitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Stomatitis and their status?
- What are the key designations that have been granted to the emerging drugs?
This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Astellas Pharma
- Celgene
- Galera Therapeutics
- Izun Pharma Ltd
- Otsuka Pharmaceuticals
- Soligenix
- MORE
Introduction
Executive Summary
Stomatitis: Overview
In-depth Commercial Assessment
Stomatitis Key Products
Stomatitis- Unmet Needs
Stomatitis- Market Drivers and Barriers
Stomatitis- Future Perspectives and Conclusion
Stomatitis Analyst Views
Stomatitis Key Companies
Appendix
List of Tables
Table 1 Total Products for Stomatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Stomatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
Stomatitis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- Stomatitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Stomatitis Key Products
Stomatitis- Unmet Needs
Stomatitis- Market Drivers and Barriers
Stomatitis- Future Perspectives and Conclusion
Stomatitis Analyst Views
Stomatitis Key Companies
Appendix
List of Tables
Table 1 Total Products for Stomatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Stomatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
- Galera Therapeutics
- Otsuka Pharmaceuticals
- Enzychem Lifesciences Corporation
- Izun Pharma Ltd
- Soligenix
- Santalis Pharmaceuticals, Inc.
- Astellas Pharma
- Access Pharmaceuticals, Inc.
- Vyriad, Inc.
- Spherium Biomed
- Celgene
Note: Product cover images may vary from those shown
